Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 91, Issue 3, Pages 283-291Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2014.03.004
Keywords
Acute leukemia; Topoisomerase H; Transcription factory; MLL; AICDA; Translocation; Recombinome
Categories
Funding
- NIH [CA10504]
Ask authors/readers for more resources
Rearrangements of the MLL gene involve multiple partners and are implicated in both therapy related acute leukemia [tAL] and infant acute leukemia. For these diseases, recently compiled clinical data confirms an elevated frequency of such breakpoints within a 4 kb tract between exon 11 and a region of structural instability adjacent to exon 12. Linked primarily to cases of tAL, interference with topoisomerase II activity may either contribute to the initial DNA lesion directly or indirectly by, for example, providing a physical block to transcription progression. Alternatively, sites of fragmentation may be mis-repaired, guided by intergenic spliced transcripts of the participating genes. Co-transcription of MLL: and potential fusion partners may provide the localization that enhances the probability of gene interaction. An indirect role for the leukemogenic activity of topoisomerase II inhibitors would imply that the negative consequences of their use may be separated from their therapeutic effects. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available